Table 1 Characteristics of included studies
NO | Author | Azithromycin group | Control group | Jada scores | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Number | Age (years) | Female (n) | Body mass index (kg/m.2) | FEV1 (L) | Methods | Number | Age (years) | Female (n) | Body mass index (kg/m.2) | FEV1 (L) | Methods | |||
1 | Valery 2013 | 45 | 3.99 ± 2.14 | 19 | – | – | azithromycin (30 mg/kg) once a week for up to 24 months | 44 | 4.22 ± 2.30 | 23 | – | – | matched placebo | 4 |
2 | Diego 2013 | 16 | 57 ± 11 | 9 | 27 ± 1 | 1.48 ± 0.8 | Azithromycin 250 mg three times per week during 3 months | 14 | 61 ± 12 | 7 | 24 ± 2 | 1.63 ± 0.7 | Matched placebo | 4 |
3 | Altenburg 2013 | 43 | 59.9 ± 12.3 | 25 | 23.0 ± 3.4 | – | Azithromycin (250 mg daily) for 12 months | 40 | 64.6 ± 9.1 | 28 | 24.5 ± 4.0 | – | Matched placebo | 5 |
4 | Wong 2012 | 71 | 60.9 ± 13.6 | 48 | 28.8 ± 7.2 | 1.87 ± 0.74 | 500 mg azithromycin three times a week for 6 months | 70 | 59.0 ± 13.3 | 50 | 28.6 ± 6.9 | 1.88 ± 0.69 | Matched placebo | 5 |